Skip to content
Medical Health Aged Care

RACGP backs national cancer screening register changes to better tackle lung cancer

Royal Australian College of GPs 2 mins read

The RACGP has welcomed the Albanese Government expanding the National Cancer Screening Register to help tackle lung cancer and called for key improvements to the register so that GPs and patients can get the most out of it.

It comes following the Government today introducing the National Cancer Screening Register Amendment Bill 2024, which adds lung cancer to the cancers incorporated in the register. This will support earlier detection of lung cancer when treatment is most effective.

RACGP President Dr Nicole Higgins said that expanding the register was a positive step forward.

“This is a smart public health decision,” she said.

“Lung cancer must be taken very seriously. In 2021, it was the most common cause of cancer death in Australia, in that year there were well over 8,000 lung cancer deaths. The National Cancer Screening Register is such an important asset because it invites and reminds eligible patients to get screened for cancers that could take their life. Many people are busy in their lives and have other things front of mind, so prompting them to get tested or screened can be the difference between finding a cancer in time or a terminal diagnosis.

“The register also creates a useful safety net by encouraging patients and their healthcare providers, including GPs, to take the next steps in terms of screening so that they stand the highest chance of a successful outcome. There is nothing anywhere else in the world quite like it. The register creates a national platform to underpin the Government’s approach to tackling bowel cancer, cervical cancer, and now, thankfully, lung cancer.”

Dr Higgins said that this was an opportunity to improve the register and make it even more valuable for GPs and patients.

“The screening register is a great thing, so let’s get the details right,” she said.

“The Government must urgently fix some problems concerning how the register integrates with existing general practice systems called clinical information systems, or CISs. There are issues relating to connectivity difficulties and delays, with the software only working sporadically, the last thing busy GPs and practice teams need. Also, the process for accessing the information we need during consults with patients is notoriously slow, limiting our ability to take full advantage of this register and do the best for our patients. So, we urge the Government to work with us and make sure the entire process is seamless and responsive for all GPs and practice teams across Australia.

“Moreover, let’s cut red tape. Many GPs are reluctant to complete time-consuming administrative work generated from the register system. If these processes are important, we should be funded to complete them, or they should be automated from within general practice CISs. We just don’t have that extra time to be tied up with this work, caring for our patients must come first.

“Finally, the Government should strongly consider the next step of adding breast screening programs to the register. We understand that breast cancer screening programs are administered by the states and territories; however, let’s find a solution so that this deadly cancer is incorporated too.”


Contact details:

Media team: 03 8699 0992 media@racgp.org.au

 

Follow us on Twitter: @RACGP and Facebook.

More from this category

  • Medical Health Aged Care
  • 13/09/2024
  • 12:40
Zenas BioPharma

Zenas BioPharma Announces Pricing of Upsized Initial Public Offering

WALTHAM, Mass., Sept. 12, 2024 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. (“Zenas”), (Nasdaq: ZBIO) a clinical-stage global biopharmaceutical company committed to being a leader in the development and commercialization of transformative immunology-based therapies, today announced the pricing of its upsized initial public offering of 13,235,294 shares of its common stock at an initial public offering price of $17.00 per share. All of the shares are being offered by Zenas. The gross proceeds from the offering, before deducting underwriting discounts and commissions and other offering expenses, are expected to be approximately $225.0 million. Zenas’ common stock is expected to begin trading…

  • Medical Health Aged Care
  • 13/09/2024
  • 12:31
Dementia Australia

New report reinforces dementia as chronic disease of 21st century

Updates to the Dementia in Australia report, released today by the Australian Institute of Health and Welfare (AIHW), reinforce that dementia is an urgent public health issue. Dementia is the second leading cause of death in Australia, the leading cause of death of women, the second leading cause of disease burden overall, and the leading cause of burden for people aged 65 and over. Dementia Australia CEO Professor Tanya Buchanan saidthe report highlights the enormity and impact of dementia in Australia as the chronic disease of the 21st century. “Despite the growing number of Australians diagnosed with dementia – there…

  • Medical Health Aged Care, Science
  • 13/09/2024
  • 11:08
La Trobe University

Centre to play key role in global AI medical research

Artificial intelligence promises to unlock new cures for cancer and other diseases by revolutionising the speed, cost and availability of personally designed drugs and enabling these to be tested on “digital twins" before being given to patients. AI will enable broad-spectrum like chemotherapy to be replaced by these more personalised, better targeted treatments. Scientists at La Trobe University's new Australian Centre for Artificial Intelligence in Medical Innovation (ACAMI), launched today, will also apply AI techniques to mRNA therapy development to enable faster design of more precise and effective treatments. Vice-Chancellor Professor Theo Farrell said ACAMI would sit within La Trobe’s…

Media Outreach made fast, easy, simple.

Feature your press release on Medianet's News Hub every time you distribute with Medianet. Pay per release or save with a subscription.